Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SERPINE1 | P05121 | 2/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | TDO2 | P48775 | 1/20 | 0.32 |
| ▸ | METAP2 | P50579 | 1/20 | 0.31 |
| ▸ | NPY1R | P25929 | 1/20 | 0.31 |
| ▸ | NPY2R | P49146 | 1/20 | 0.31 |
| ▸ | NPY4R | P50391 | 1/20 | 0.31 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1551795 | 1.00 | SLC18A3 (0.41) | SLC18A3CHRM2CHRM1CHRM4CHRM3 | |
| SCHEMBL111167 | 1.00 | SLC18A3 (0.41) | SLC18A3CHRM2CHRM1CHRM4CHRM3 | |
| SCHEMBL1551796 | 1.00 | SLC18A3 (0.41) | SLC18A3CHRM2CHRM1CHRM4CHRM3 | |
| SCHEMBL1551168 | 1.00 | SLC18A3 (0.41) | SLC18A3CHRM2CHRM1CHRM4CHRM3 | |
| SCHEMBL4148362 | 1.00 | SLC18A3 (0.41) | SLC18A3CHRM2CHRM1CHRM4CHRM3 | |
| Acetic Acid SCHEMBL15140949 | 0.96 | SLC18A3 (0.42) | SLC18A3CHRM2CHRM1CHRM4CHRM3 | |
| SCHEMBL15187679 | 0.96 | CHRM2 (0.43) | SLC18A3CHRM2CHRM1CHRM4CHRM3 | |
| SCHEMBL29155391 | 0.87 | MAPT (0.43) | SLC18A3CHRM2CHRM1CHRM4CHRM3 | |
| SCHEMBL1472615 | 0.86 | EPHX1 (0.35) | SERPINE1CYP19A1NPY1RNPY2RNPY4R | |
| SCHEMBL29446936 | 0.84 | SLC18A3 (0.36) | SLC18A3CHRM2CHRM1CHRM4CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2211829-B1 | IMPROVEMENT OF THE FRAGRANCE EFFECT OF PERFUME ESTERS | HENKEL AG & CO KGAA (DE) | 2011-04-27 | — | — | EP | claimed |
| US-20100210496-A1 | Fragrance Effect of Perfume Esters | BESSLER CORNELIUS | 2010-08-19 | — | — | US | claimed |
| US-11744785-B2 | Use of volatile compositions to limit or eliminate the perception of malodor | FIRMENICH SA (CH) | 2023-09-05 | — | — | US | disclosed |
| US-20230233425-A1 | USE OF VOLATILE COMPOSITIONS TO LIMIT OR ELIMINATE THE PERCEPTION OF MALODOR | FIRMENICH SA (CH) | 2023-07-27 | — | — | US | disclosed |
| US-20200345601-A1 | USE OF VOLATILE COMPOSITIONS TO LIMIT OR ELIMINATE THE PERCEPTION OF MALODOR | FIRMENICH SA (CH) | 2020-11-05 | — | — | US | disclosed |
| US-8557832-B2 | Aryl methyl benzoquinazolinine M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2013-10-15 | — | — | US | disclosed |
| US-20110224198-A1 | ARYL METHYL BENZOQUINAZOLININE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME LLC | 2011-09-15 | — | — | US | disclosed |
| US-20100210496-A1 | Fragrance Effect of Perfume Esters | BESSLER CORNELIUS | 2010-08-19 | — | — | US | disclosed |
| US-4874473-A | ADDING ADJUVANT TO CHANGE VAPOR PRESSURE, IMPROVE RESOLUTION | BAYER AKTIENGESELLSCHAFT (DE) | 1989-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11744785-B2 | Use of volatile compositions to limit or eliminate the perception of malodor | TAS2R8, TRPA1, TAS2R10 | SLC18A3 159/4885CHRM2 107/4885CHRM1 93/4885 |
| US-20110224198-A1 | ARYL METHYL BENZOQUINAZOLININE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, OPRL1, CHRM2 | SLC18A3 848/4885CHRM2 3/4885CHRM1 1/4885 |
| US-20200345601-A1 | USE OF VOLATILE COMPOSITIONS TO LIMIT OR ELIMINATE THE PERCEPTION OF MALODOR | TAS2R8, TRPA1, TAS2R10 | SLC18A3 159/4885CHRM2 107/4885CHRM1 93/4885 |
| US-20230233425-A1 | USE OF VOLATILE COMPOSITIONS TO LIMIT OR ELIMINATE THE PERCEPTION OF MALODOR | TAS2R8, TRPA1, TAS2R10 | SLC18A3 159/4885CHRM2 107/4885CHRM1 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.